606 related articles for article (PubMed ID: 19627290)
1. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
Hess G; Preblick R; Hill J; Plauschinat CA; Yaskin J
Congest Heart Fail; 2009; 15(4):170-5. PubMed ID: 19627290
[TBL] [Abstract][Full Text] [Related]
2. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
Brackbill ML; Bashaw-Keaton R; Sytsma CS
Am J Manag Care; 2007 Oct; 13(10):568-70. PubMed ID: 17927461
[TBL] [Abstract][Full Text] [Related]
4. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
[TBL] [Abstract][Full Text] [Related]
5. Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors.
Setoguchi S; Levin R; Winkelmayer WC
Int J Cardiol; 2008 Apr; 125(2):172-7. PubMed ID: 17997175
[TBL] [Abstract][Full Text] [Related]
6. Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Levy PD; Nandyal D; Welch RD; Sun JL; Pieper K; Ghali JK; Fonarow GC; Gheorghiade M; O'Connor CM
Am Heart J; 2010 Feb; 159(2):222-230.e2. PubMed ID: 20152220
[TBL] [Abstract][Full Text] [Related]
7. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation.
Nieuwlaat R; Eurlings LW; Cleland JG; Cobbe SM; Vardas PE; Capucci A; López-Sendòn JL; Meeder JG; Pinto YM; Crijns HJ
J Am Coll Cardiol; 2009 May; 53(18):1690-8. PubMed ID: 19406345
[TBL] [Abstract][Full Text] [Related]
8. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.
Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF.
Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
J Card Fail; 2007 Nov; 13(9):722-31. PubMed ID: 17996820
[TBL] [Abstract][Full Text] [Related]
11. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
[TBL] [Abstract][Full Text] [Related]
13. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
14. Improving the management of patients after myocardial infarction, from admission to discharge.
Amin A
Clin Ther; 2006 Oct; 28(10):1509-39. PubMed ID: 17157110
[TBL] [Abstract][Full Text] [Related]
15. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
Fonarow GC; Stough WG; Abraham WT; Albert NM; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
J Am Coll Cardiol; 2007 Aug; 50(8):768-77. PubMed ID: 17707182
[TBL] [Abstract][Full Text] [Related]
16. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
O'Connor CM; Abraham WT; Albert NM; Clare R; Gattis Stough W; Gheorghiade M; Greenberg BH; Yancy CW; Young JB; Fonarow GC
Am Heart J; 2008 Oct; 156(4):662-73. PubMed ID: 18926148
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Tokmakova M; Solomon SD
Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
Austin PC; Tu JV; Ko DT; Alter DA
CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
[TBL] [Abstract][Full Text] [Related]
20. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis.
Setoguchi S; Glynn RJ; Avorn J; Mittleman MA; Levin R; Winkelmayer WC
J Am Coll Cardiol; 2008 Apr; 51(13):1247-54. PubMed ID: 18371553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]